Clinical trial evidence is building for moving checkpoint blockade immunotherapy forward in the treatment timeline for non–small cell lung cancer, but improving patient selection for these therapies remains a key challenge.
Original Article: Evidence Grows for Earlier Immunotherapy in NSCLC